Anticoagulation for atrial fibrillation in adults with advanced kidney disease - Final version - September 2025

Oct 12, 2026

Uploaded by hdkawk

Clinical practice guideline on anticoagulation for atrial fibrillation in adults with advanced kidney disease, providing final consolidated content dated September 2025. Includes review information, leadership and multidisciplinary working group membership, and acknowledgements to expert Delphi panel contributors. The document outlines executive summary, recommendations, and sections covering background and methods, kidney function estimation for dosing, stroke/bleeding risk scores, treatment options for NVAF thromboprophylaxis, monitoring and follow-up, and additional areas of interest.

LanguageEnglish

CategoryGeneral

FormatPDF

Pages93

Reading Time33 min

AccessFree to download

Acknowledgements

Contents

Executive Summary

Summary of recommendations

Section 1: Background, aims and concise methods

Section 2: Kidney function estimates for anticoagulant dosing

Section 3: The use of risk scores for stroke and bleeding assessment

Section 4: Treatment options for NVAF thromboprophylaxis

Section 5: Monitoring and follow up

Section 6: Areas of interest

Section 7: Lay executive summary

Clinical Practice Guideline: Anticoagulation for atrial fibrillation in adults with advanced kidney disease Final version: September 2025 Review date: September 2028 Co-Chairs: Kathrine Parker, Manchester University NHS Foundation trust and University of Manchester Dr Albert Power, University of Bristol and Imperial College London Guideline working group: Yvonne Bernes, Sheffield Teaching Hospitals NHS Trust Dr Kate Bramham, St Thomas’s Hospital Dr Richard Buka, University of Birmingham Dr Satarupa Choudhuri, Northern Care Alliance NHS Foundation trust Dr Mark Davies, Cardiff and Vale University Hospital Board Dr Maria A Gauci, Bradford Teaching Hospital NHS Foundation Trust Lauren Hall, University Hospitals Plymouth NHS Foundation Trust Dr John Hartemink, Manchester University NHS Foundation trust Nicola Korn, Norfolk and Norwich University Hospitals NHS Foundation Trust Penny Lewis, University of Manchester Prof. Gregory Y.H. Lip, Liverpool John Moores University & Liverpool Heart & Chest Hospital NHS Trust Katy Mills, University Hospitals North Midlands Dr Anneka Mitchell, University Hospitals Plymouth NHS Trust Dr Lara Roberts, Kings College Hospital NHS Foundation Trust Huw Rowswell, University Hospitals Plymouth NHS Trust Dr Hannah Stacey, Mid and South Essex NHS Foundation trust Katherine Stirling, Leeds Teaching NHS Foundation Trust Prof. Jecko Thachil, Manchester University NHS Foundation Trust and University of Manchester Dr Honey Thomas, Northumbria Healthcare NHS Foundation Trust Fang Feng Ting, Watford General Hospital Dr Jung Tsang, Bodey Medical Practice and University of Manchester Isaac Tseng, Oxford University Hospitals Dr Andrew Turley, South Tees NHS Foundation Trust Alan Hancock, Patient representative Donna Lewis, Patient representative Ed Jenkinson, Patient representative Alan Craig*, Patient representative Acknowledgements Acknowledgements to expert Delphi panel members who provided their expertise in the development of the consensus statements used in this guideline: Prof. Raza Alikhan, University Hospital Wales Sotiris Antoniou, Barts Heart Centre Joanne Bateman, Countess of Chester Hospital Dr Kate Bramham, R St Thomas’s Hospital Dr Richard Buka, University of Birmingham Prof. John Camm, St. George's University of London Dr Alexander Cohen, Guy's and St Thomas' Hospital Prof. Andrew Davenport, University College, London Prof. Charles Ferro, University Hospitals Birmingham Prof Philip Kalra, Salford Royal NHS Foundation Trust & University of Manchester Prof Gregory Y.H. Lip, Liverpool John Moores University & Liverpool Heart & Chest Hospital NHS Trust Dr Albert Power, North Bristol NHS Trust Dr Lara Roberts, Kings College Hospital NHS Foundation Trust Dr Susie Shapiro, Oxford University Hospitals Katherine Stirling, Leeds Teaching NHS Foundation Trust Dr David Sutton, University Hospitals of North Midlands Dr Will Thomas, Cambridge University Hospitals Isaac Tseng, Oxford University Hospitals Dr Honey Thomas, Northumbria Healthcare NHS Foundation Trust Dr Andrew Turley, South Tees NHS Foundation Trust Prof. Stephen Wheatcroft, Leeds Teaching NHS Foundation Trust & University of Leeds Kathrine Parker was supported by the National Institute for Health Research (HEE/ NIHR ICA Programme Clinical Doctoral Research Fellowship, Miss Kathrine Parker, NIHR300545) to undertake a programme of research which forms the basis for this guideline. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. Prof. Sandip Mitra supervised Kathrine Parker undertaking this work. *Alan Craig was one of the patients who kindly contributed to the work that forms part of this guideline but sadly passed away before the guideline was complete. Alan was always enthusiastic about improving kidney care for all but w

FAQs

Who led and contributed to the development of the guideline?

The guideline lists co-chairs and a multidisciplinary working group, along with acknowledgements to an expert Delphi panel and feedback from professional organizations.

What key clinical topics are covered in the guideline?

The guideline covers background and methods, kidney function estimates for anticoagulant dosing, stroke and bleeding risk scores, NVAF thromboprophylaxis treatment options, and monitoring and follow-up.

When is the final version dated, and what is the planned review date?

The final version is dated September 2025, with a stated review date of September 2028.

Oct 12, 2026

Uploaded by hdkawk